# Regeneron Pharmaceuticals, Inc. (REGN) — Q4-2017 Earnings Results

**Report date:** 2018-02-08 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q4-2017

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Down 3.58%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $5.23 | N/A | +17.08% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management conveyed a positive outlook on earnings performance while emphasizing their commitment to innovation. However, the lack of revenue guidance left some investors uncertain.

**Key quotes:**

> Management expressed satisfaction with the EPS performance despite not providing revenue figures.

> They highlighted ongoing investments in research and development as a priority.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron's earnings report showed a strong EPS performance, beating expectations by over 17%. However, the stock fell by 3.58% in reaction, likely due to the absence of revenue figures and guidance, which may have raised concerns among investors about future growth prospects.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q4-2017_